Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
Cancer Vaccines01:30

Cancer Vaccines

358
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
358
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis of Pregnancy-Associated Breast Cancer: A Systematic Review of Contemporary Observational Studies.

Medical sciences (Basel, Switzerland)·2026
Same author

Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center.

Biomedicines·2026
Same author

Comparison of Pelvic Peritonectomy vs. Rectosigmoid Resection During Hudson Procedure for Advanced Ovarian Cancer: 6-Year Experience of an ESGO-Certified Center.

Cancers·2026
Same author

Prognostic Factors in the Treatment of Advanced Endometrial Cancer Patients: 12-Year Experience of an ESGO Certified Center.

Cancers·2026
Same author

Real-World Neoadjuvant Systemic Therapy Utilization and Treatment Patterns in Patients with Early-Stage or Locally Advanced Triple-Negative Breast Cancer in Greece-The TRINITY Study.

Cancers·2025
Same author

Dissecting the Non-Immune Tumor Microenvironment in Triple-Negative Breast Cancer: Molecular Subtype-Specific Patterns and Prognostic Implications.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jun 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC.

Evangelia Bogatsa1, George Lazaridis1, Chrysoula Stivanaki1

  • 1Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou Hospital, 56429 Thessaloniki, Greece.

Cancers
|May 11, 2024
PubMed
Summary
This summary is machine-generated.

Early-stage non-small cell lung cancer (NSCLC) treatment is evolving with immune-checkpoint inhibitors (ICIs). Research focuses on optimizing ICI therapies and identifying biomarkers for better outcomes in resectable NSCLC.

Keywords:
adjuvantearlyimmune-checkpoint inhibitorsimmunotherapyneoadjuvantnon-small cell lung cancerperioperativeresectable

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Related Experiment Videos

Last Updated: Jun 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Surgery

Background:

  • Early-stage non-small cell lung cancer (NSCLC) presents challenges with poor survival and recurrence rates despite advancements.
  • The integration of immune-based therapies, mirroring strategies for advanced NSCLC, is transforming early-stage management.
  • Immune-checkpoint inhibitors (ICIs) are being explored in neoadjuvant, adjuvant, and perioperative settings for resectable NSCLC.

Purpose of the Study:

  • To review current immunotherapy treatment options for early-stage NSCLC.
  • To analyze the advantages and disadvantages of various ICI regimens.
  • To discuss persistent challenges and future directions in immunotherapy for resectable NSCLC.

Main Methods:

  • Comprehensive literature review of clinical trials and research on ICI in early-stage NSCLC.
  • Analysis of treatment strategies including monotherapy, combination therapy, and perioperative approaches.
  • Evaluation of biomarker research for predicting treatment response.

Main Results:

  • ICI regimens show promise in neoadjuvant, adjuvant, and perioperative settings for early NSCLC.
  • Ongoing research aims to personalize ICI treatments for specific patient subsets.
  • Biomarker identification is crucial for predicting response and improving survival rates.

Conclusions:

  • Immunotherapy, particularly ICIs, represents a significant advancement in the management of resectable NSCLC.
  • Optimizing treatment strategies and identifying predictive biomarkers are key to maximizing patient benefit.
  • Future research holds the potential to further refine immunotherapy approaches, ushering in a new era for early lung cancer care.